Browsing by Author Schwabe, C

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 中
Showing results 1 to 16 of 16
TitleAuthor(s)Issue DateViews
 
A phase 1 study to evaluate safety and tolerability of escalating single doses of the hepatitis B virus RNA interference drug ARC-521 in a healthy volunteer population
Proceeding/Conference:Journal of Hepatology
Gane, ESchwabe, CGiven, BSchluep, THamilton, JLai, CLLocarnini, SLau, JFerrari, CGish, R
2017
73
 
AB-729, a GalNAc-siRNA, results in robust reductions of HBV DNA and HBsAg in subjects with chronic hepatitis B infection
Proceeding/Conference:Hepatology International
Sevinsky, HGane, EDGane, EBerliba, EKim, YJHolmes, JLim, Y-SStrasser, SSukeepaisarnjaroen, WSchwabe, CJucov, ALee, ACHThi, EPHarasym, TPamulapati, GRWattamwar, PKunta, JSofia, MSevinsky, HGray, KEley, TPicchio, GSims, KDYuen, RMF
2021
11
 
Antiviral Activity, Safety, and Pharmacokinetics of Capsid Assembly Modulator NVR 3-778 in Patients with Chronic HBV Infection
Journal:Gastroenterology
Yuen, MFGane, EJKim, DJWeilert, FChan, HLYLalezari, JHwang, SGNguyen, TFlores, OHartman, GLiaw, SLenz, OKakuda, TNTalloen, WSchwabe, CKlumpp, KBrown, N
2019
33
 
ARO-HSD reduces hepatic HSD17B13 mRNA expression and protein levels in patients with suspected NASH
Proceeding/Conference:Journal of Hepatology
Gane, ESchwabe, CYoon, KTHeo, JScott, RLee, JLee, JILKweon, YOWeltman, MHarrison, STetri, BCusi, KLoomba, RChristianson, DRajicic, NMartin, JSHamilton, JYuen, RMF
2021
31
 
Dose response with the RNA interference (RNAi) therapy JNJ-3989 combined with nucleos(t)ide analogue (NA) treatment in expanded cohorts of patients (pts) with chronic hepatitis B (CHB)
Proceeding/Conference:Hepatology
Gane, EJLocarnini, SLim, THStrasser, SISievert, WCheng, WThompson, AGiven, BDSchluep, THamilton, JBiermer, MKalmeijer, RBeumont-Mauviel, MLenz, OCloherty, GWong, DKHSchwabe, CJackson, KFerrari, CLai, CLGish, RGYuen, RMF
2019
39
 
First results with RNA interference (RNAi) in chronic hepatitis b (CHB) using ARO-HBV
Proceeding/Conference:Hepatology
Gane, EJLocarnini, SLim, THStrasser, SSievert, WCheng, WThompson, AGiven, BSchluep, THamilton, JLi, ZCloherty, GWong, DKHSchwabe, CJackson, KFerrari, CLai, CLGish, RGYuen, RMF
2018
80
 
Interim safety, tolerability pharmacokinetics, and antiviral activity of ABI-H0731, a novel core protein allosteric modulator, in healthy volunteers and non-cirrhotic viremic subjects with chronic hepatitis B
Proceeding/Conference:Journal of Hepatology
Yuen, RMFAgarwal, KGane, ESchwabe, CCheng, WSievert, WKim, DJAhn, SHLim, YSVisvanathan, KRuby, ELiaw, SColonno, RLopatin, U
2018
108
 
Resistance monitoring data from treatment-naïve chronic HBV infected patients treated for 28 days with a new class a core protein allosteric modulator RO7049389 monotherapy
Proceeding/Conference:Journal of Hepatology
Zhou, XKazma, RMeinel, DZhou, YYuen, RMFGane, ESchwabe, CTanwandee, TCao, LZhou, JBo, Q
2020
27
 
RO7049389, a core protein allosteric modulator, demonstrates robust anti-HBVactivity in chronic hepatitis B patients and is safe and well tolerated
Proceeding/Conference:Journal of Hepatology
Gane, ELiu, AYuen, RMFSchwabe, CBo, QDas, SGoa, LZhou, XWang, YCoakley, EJin, Y
2018
87
 
RO7049389, a core protein allosteric modulator, is safe and well tolerated in healthy volunteers and demonstrates potent anti-HBV activity in a phase 1 trial
Proceeding/Conference:Journal of Viral Hepatitis
Gane, ELiu, AYuen, RMFSchwabe, CBo, QDas, SBGoa, LZhou, XWang, YCoakley, EJin, Y
2018
95
 
Safety and pharmacodynamics of the GALNAC-siRNA AB-729 in subjects with chronic hepatitis B infection
Proceeding/Conference:Hepatology
Yuen, RMFBerliba, EKim, YJHolmes, JALim, YSStrasser, SISchwabe, CJucov, ALee, ACHThi, EPHarasym, TPamulapati, GRWattamwar, PKunta, JSofia, MJSevinsky, HGray, KEley, TPicchio, GRSims, KGane, EJ
2020
14
 
Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial
Journal:The Lancet Gastroenterology & Hepatology
Yuen, MFAgarwal, KGane, EJSchwabe, CAhn, SHKim, DJLim, YSCheng, WSievert, WVisvanathan, KRuby, ELiaw, SYan, RHuang, QColonno, RLopatin, U
2020
28
 
Safety, tolerability and pharmacokinetics (pk) of single and multiple doses of alg-010133, an s-antigen transport inhibiting oligonucleotide polymer (stops) for the treatment of chronic hepatitis B
Proceeding/Conference:Journal of Hepatology
Gane, EYuen, RMFYogaratnam, JLe, KVuong, JChristopher, WGohil, VSchwabe, CAgarwal, KJucov, ALiu, JWLin, T-IBlatt, LChanda, SMcClure, MFry, J
2021
6
 
Short interfering RNA JNJ-3989 combination therapy in chronic hepatitis B shows potent reduction of all viral markers but no correlate was identified for HBsAg reduction and baseline factors
Proceeding/Conference:Journal of Hepatology
Gane, ELocarnini, SLim, THStrasser, SSievert, WCheng, WThompson, AGiven, BSchluep, THamilton, JBiermer, MKalmeijer, RBeumont-Mauviel, MLenz, ODe Ridder, FCloherty, GWong, DKHSchwabe, CJackson, KFerrari, CLai, CLGish, RGYuen, RMF
2021
40
 
Short term RNA interference therapy in chronic hepatitis B using JNJ-3989 brings majority of patients to HBsAg < 100 IU/ml threshold
Proceeding/Conference:Journal of Hepatology
Yuen, RMFLocarnini, SLim, THStrasser, SSievert, WCheng, WThompson, AGiven, BSchluep, THamilton, JCloherty, GWong, DKHSchwabe, CJackson, KFerrari, CLai, CLGish, RGGane, E
2019
65
 
Short-term treatment with RNA interference therapy, JNJ-3989, results in sustained hepatitis B surface antigen suppression in patients with chronic hepatitis B receiving nucleos(t)ide analogue treatment
Proceeding/Conference:Journal of Hepatology
Gane, ELocarnini, SLim, THStrasser, SSievert, WCheng, WThompson, AGiven, BSchluep, THamilton, JBiermer, MKalmeijer, RBeumont-Mauviel, MLenz, OCloherty, GWong, DKHSchwabe, CJackson, KFerrari, CLai, CLGish, RGYuen, RMF
2020
73
Showing results 1 to 16 of 16